Arimidex Shortage: What Providers and Prescribers Need to Know in 2026

For clinicians managing patients on anastrozole (Arimidex) for hormone receptor-positive breast cancer, understanding the current supply landscape is essential for maintaining uninterrupted care. This guide covers the 2026 availability status, clinical considerations for switching, prescribing strategies, and how to communicate proactively with your patients.

Current Availability Status (2026)

As of 2026, anastrozole is not on the FDA's official drug shortage database. Generic anastrozole is manufactured by multiple companies including Teva, Mylan (Viatris), Hikma, Sun Pharma, and others, providing meaningful supply chain redundancy. The brand-name Arimidex (AstraZeneca) patent expired circa 2010-2012, and the market has largely converted to generic.

However, localized inventory issues at specific pharmacy locations remain a real patient burden. A brief manufacturing disruption at one generic supplier in early 2025 caused temporary price increases of approximately 12% nationally. These types of episodic disruptions — while not official shortages — can still cause patients to miss doses or delay refills, with potential clinical implications for long-term hormone suppression.

Clinical Implications of Missed Doses

Anastrozole has a half-life of approximately 46 hours. Clinically significant estrogen suppression (approximately 70% reduction within 24 hours; approximately 80% at 14 days of steady dosing) means that estradiol levels will begin rising within days of missed doses. Estradiol suppression was maintained for up to 6 days after cessation of daily dosing in pharmacokinetic studies.

For most patients in long-term adjuvant therapy, a brief 1-3 day gap is unlikely to produce a meaningful clinical setback. However, patients in active treatment for advanced or metastatic disease, or those in the early months of adjuvant therapy establishing steady-state suppression, warrant more urgent attention to refill gaps. Counsel patients to contact your office immediately if they anticipate being without medication for more than 2-3 days.

Therapeutic Alternatives: Clinical Considerations for Switching

If anastrozole is unavailable in a patient's area, two primary therapeutic alternatives within the aromatase inhibitor class are available:

Letrozole (Femara, 2.5 mg daily)

Letrozole is the most pharmacologically analogous substitute. Both are non-steroidal, competitive aromatase inhibitors. Clinical trial data (BIG 1-98 for letrozole; ATAC for anastrozole) demonstrate comparable disease-free survival outcomes as adjuvant therapy in postmenopausal HR+ early breast cancer. Letrozole may achieve slightly greater estrogen suppression in some pharmacodynamic studies, though clinical significance is not established. No washout or dose titration is required when switching between these agents — a direct switch is generally well-tolerated. Monitor for the standard class-related adverse effects: bone mineral density loss, lipid changes, and musculoskeletal symptoms.

Exemestane (Aromasin, 25 mg daily with food)

Exemestane is a steroidal, irreversible aromatase inactivator. It is FDA-approved for adjuvant treatment in postmenopausal HR+ early breast cancer (typically after 2-3 years of tamoxifen) and for advanced breast cancer. Exemestane may cause fewer musculoskeletal adverse effects than the non-steroidal AIs in some patients — a relevant consideration for patients experiencing significant arthralgia on anastrozole. Note that exemestane must be taken with food for adequate absorption, unlike anastrozole and letrozole. It has minor androgenic activity due to its steroidal structure, which may have implications for lipid profiles.

Prescribing Strategies to Minimize Supply Disruption

Several prescribing practices can reduce the likelihood that your patients will experience refill gaps:

• Prescribe 90-day supplies. A 90-day supply reduces the number of refill events per year from 12 to 4, dramatically reducing the chance of being caught without medication during a temporary pharmacy stock-out.
• Consider mail-order pharmacies. Many insurance plans cover mail-order 90-day supplies of anastrozole at a lower copay. These pharmacies often have more reliable inventory for maintenance oncology medications.
• Write the prescription as generic anastrozole. Specifying generic allows the pharmacist to substitute any manufacturer's version, providing more flexibility when one manufacturer's supply is low.
• E-prescribe at the appointment. Sending the prescription immediately after the visit gives the patient maximum lead time and avoids the common scenario where a patient picks up their last pill before the new prescription is ready.
• Flag high-risk patients. Patients with limited transportation, rural addresses, or complex insurance situations are at highest risk of refill gaps. Proactive care coordination for these patients can prevent missed doses.

Patient Communication Guidance

Consider providing patients with the following guidance proactively:

• Start calling for refills when 10 or more days of medication remain, not when the bottle is empty
• If your primary pharmacy is out, call other pharmacies in your area — or use medfinder.com to search nearby pharmacies
• Contact this office immediately if you anticipate being without anastrozole for more than 2-3 days — do not stop on your own without guidance

Resources for Providers

For practices looking for a solution to the pharmacy search problem, medfinder for providers offers a service where pharmacies near a patient's location are called to check availability — reducing the burden on nursing staff to make individual pharmacy calls on behalf of patients who report refill problems.

Read our companion article: How to help your patients find Arimidex in stock: A provider's guide.